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Paper
European molecular epidemiology and strain
diversity of feline calicivirus
J. Hou, F. Sánchez-Vizcaíno, D. McGahie, C. Lesbros, T. Almeras, D. Howarth, V. O’Hara,
S. Dawson, A. D. Radford
Feline calicivirus (FCV) causes a variable syndrome of upper respiratory tract disease, mouth
ulcers and lameness. A convenience-based prospective sample of oropharyngeal swabs
(n=426) was obtained from ﬁve countries (France, Germany, Greece, Portugal and the UK).
The prevalence of FCV by virus isolation was 22.2 per cent. Multivariable analysis found that
animals presenting with lymphoplasmacytic gingivitis stomatitis complex were more likely
to test positive for FCV infection. Furthermore, vaccinated cats up to 48 months of age were
signiﬁcantly less likely to be infected with FCV than unvaccinated animals of similar ages.
Phylogenetic analysis based on consensus sequences for the immunodominant region of the
capsid gene from 72 FCV isolates identiﬁed 46 strains. Thirteen of the 14 strains with more
than one sequence were restricted to individual regions or sites in individual countries; the
exception was a strain present in two sites close to each other in France. Four strains were
present in more than one household. Five colonies, four of which were rescue shelters, had
multiple strains within them. Polymerase sequence suggested possible rare recombination
events. These locally, nationally and internationally diverse FCV populations maintain a
continuous challenge to the control of FCV infection and disease.
Introduction
Feline calicivirus (FCV) is one of the most frequently reported
pathogens causing upper respiratory tract and oral disease in cats
(Radford and others 2009). Following FCV infection, most cats
develop acute respiratory disease and oral ulceration (Pesavento
and others 2008). Less frequently, more systemic signs including
acute arthritis/limping syndrome (Pedersen and others 1983,
Dawson and others 1994, TerWee and others 1997) and
haemorrhagic-like fever may be seen (Pedersen and others 2000,
Coyne and others 2006a). Most cats with a severe oral inﬂamma-
tory syndrome called lymphoplasmacytic gingivitis stomatitis
complex (LGSC) also test positive for FCV, although Koch’s pos-
tulates have not been proven (Knowles and others 1991, Poulet
and others 2000). Following infection with FCV, many cats shed
virus beyond the resolution of clinical signs, and those shedding
for more than 30 days are termed carriers (Wardley 1976,
Wardley and Povey 1977). Most cats do seem to eventually clear
infection, and it is thought the majority of ‘carriers’ are undergo-
ing repeated reinfections, with only a minority being truly per-
sistently infected (Coyne and others 2007b).
Vaccines against FCV have been available for over forty years.
Several vaccine antigens are used including FCV-F9 in live vac-
cines, and in inactivated vaccines, either FCV-225 or a combin-
ation of FCV-431 and FCV-G1 (Radford and others 2009).
Although pre-existing immunity, either from vaccination or pre-
vious infection, does ameliorate clinical signs, it does not induce
sterilising immunity. As a result, the prevalence of FCV in the
general cat population remains high (Wardley and others 1974),
especially among cats living in colonies or shelters (Coutts and
others 1994, Radford and others 2001b, Bannasch and Foley
2005, Helps and others 2005).
As an RNA virus, FCV evolves quickly (Radford and others
1999a, Coyne and others 2007b). Despite this, sufﬁcient
sequence and antigenic relatedness persists to allow FCV var-
iants to be considered a single diverse serotype (Povey and
Ingersoll 1975) and genotype (Glenn and others 1999).
Phylogenetic analysis typically results in a ‘star-like’ phylogeny.
Lack of statistical support for subspecies clusters means it has
not proved possible to identify robust groupings of FCV either
on spatial, temporal or clinical grounds.
Using this inherent genetic variability, the molecular epi-
demiology of FCV has been studied at various population levels.
In individual households, one or a small number of strains can
circulate often at high prevalence, with extensive genetic vari-
ation driven by positive selection (Radford and others 2003,
Coyne and others 2007b). In rescue shelters, many strains can be
present, and where biosecurity is good, these pass through the
colony with little evidence of transmission (Radford and others
2001b, Coyne and others 2007a). At a regional or community
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level, a highly complex genetic landscape can exist with many
10 s of strains co-circulating, with only rare cases of transmission
between practices at the national (UK) level (Coyne and others
2012).
The primary aim of this study was to see whether the popu-
lation structure of viruses previously seen in the UK is mirrored
when data from multiple countries is included.
Materials and methods
Sample collection
Samples were collected from ﬁve countries: France (ﬁve sites in
the Paris area), UK (two sites: Bangor (Northern Ireland) and
Northampton), Portugal (two sites: Mem Martins and Lisbon
area), Greece (one site: Thessaloniki) and Germany (three sites:
Lippstadt, Berlin and Achim). At each site, a private veterinary
practitioner was recruited based on convenience by the project
sponsor, and asked to sample two types of cats; healthy cats not
vaccinated against FCV for at least 1 month (to reduce the prob-
ability of isolating vaccine strains), and those cats with clinical
signs typical of FCV infection (for example coryza or LGSC).
For each cat whose owner gave consent, a plain cotton-
tipped swab was used to collect an oropharyngeal saliva sample
and placed in 2 ml viral transport medium (40 per cent L15/Mac
Coy’s (v/v) cell culture media, 60 per cent freezing excipient).
These were stored locally at −18°C then shipped as a batch to
the laboratory on dry ice. With each sample a short question-
naire was completed by the attending veterinary surgeon and
owner, capturing demographic data, disease and vaccination
history.
The non-invasive nature of this project and anonymised data
collection meant that formal ethical committee approval was
not necessary. However, informed owner consent was a stipula-
tion before samples were collected.
Virus isolation
Diagnosis of FCV and feline herpesvirus type 1 (FeHV-1) was by
demonstrating typical cytopathic effect on conﬂuent monolayers
of feline embryo A cells. Samples were only reported negative
following a second negative passage. Positive isolates were stored
at −80°C (Knowles and others 1990).
Statistical analysis
A parametrical bootstrap approach was used to test country and
sites as random effects based on a hypothesis of the form H0:
σ2=0. The estimate P value was 0.99 for country and 0.09 for
sites. Thus, the level of between-country and between-site vari-
ability was not considered sufﬁcient to incorporate random
effects in a multivariable model.
A multivariable logistic regression analysis was conducted to
model the probability of being infected with FCV. The model
was ﬁtted in R (V.3.01) using the ‘glm’ function from ‘aod’
package. Risk factors considered within the model included the
country and site within the country where the samples were col-
lected, sex, whether a cat lived outdoors, neutering status, FCV
vaccination status, age and presence of the following clinical
signs: ocular discharge, sneezing, gingivitis, nasal discharge,
coughing, oral ulcers, conjunctivitis, stomatitis and LGSC.
Visual inspection of the data indicated a curvilinear relationship
between the proportion of FCV infected cats and age (Fig 1a),
thus a quadratic term in age was included to ﬁt the model. Age
was centred to make the model interpretation easier and to
reduce the correlation between the linear and quadratic terms.
Two-way interactions between age and its quadratic term and
the factors neutering and vaccination status were included in the
initial multivariable model. A stepwise model selection by akaike
information criterion (AIC) was conducted using the R
command ‘step’ of the ‘stats’ package. A backward selection pro-
cedure was used to reﬁt the model eliminating terms from the
ﬁtted model based on a likelihood ratio test (P>0.05)(Faraway
2006).
Detailed information about the number of cats living in the
same household (NCH) was only available for 66 per cent of the
observations in the multivariable analysis. Therefore, to avoid
reducing the numbers included in the multivariable model, the
impact of NCH on FCV infection was only assessed by univari-
able logistic regression.
RNA extraction, reverse transcription-PCR
RNAs were extracted from positive samples (second passage or
less) (QIAmp viral RNA Mini Kit; Qiagen). For every three
samples, one negative control was included from uninfected cell
cultures. Reverse transcription was performed using 200 ng
random hexamers (Superscript III, Invitrogen), according to
manufacturer ’s guidelines.
Capsid ampliﬁcation: A 529-nucleotide region of the capsid
gene, equivalent to residues 6406-6934 of FCV strain F9 (Carter
and others 1992) and incorporating immunodominant regions C
and E (Seal and others 1993, Radford and others 1999b), was
ampliﬁed as previously described (Coyne and others 2007b,
2012). Brieﬂy, each 50 ml reaction contained 2 ml cDNA, 45 ml
1.1×Reddy mix (Thermo Scientiﬁc), 1 ml nuclease-free water
and 3.2 ng each of forward and reverse primers (Table 1). In early
experiments, primers M13cap2F/T7cap2R were most cross-
reactive and so all PCRs were initially conducted with these:
only samples testing negative were subsequently attempted with
the additional primers.
Thermal cycling consisted of DNA denaturation (95°C, 2
min), followed by 40 cycles of denaturation (95°C, 30 s), primer
annealing (45–55°C, 30 s) and primer extension (72°C, 90 s). A
ﬁnal extension was performed at 72°C (5 min).
Polymerase ampliﬁcation: A 486-nucleotide region correspond-
ing to the 30 end of the FCV POL region was ampliﬁed from the
same cDNA template using Reddy-Mix (ABgene) according to
the manufacturers’ instructions, in 50 μl reactions containing
100 ng each of the primers M13-53D and T7-33D (Coyne and
others 2006b) (Table 1). Thermal cycling consisted of denatur-
ation (95°C, 4 minutes), followed by 40 cycles of denaturation
(95°C, 60 s), primer annealing (55°C, 60 s) and primer extension
(72°C, 3 minutes). A ﬁnal extension was performed at 72°C
(5 minutes).
Nucleotide sequence and phylogenetic analysis
Amplicons were puriﬁed (QIAquick PCR puriﬁcation, Qiagen),
quantiﬁed (Genequant) and sequenced bidirectionally (Source
Bioscience). The authors have previously found this method to
be >99 per cent reproducible (Coyne and others 2007b). Forward
and reverse sequences were aligned and manually corrected
(Chromas Pro, Technelysium). Pairwise p-distances between
sequences, and Kimura 2-parameter Neighbour-joining trees
with 1000 bootstrap replicates were calculated using MEGA
V.5.2.2 (Tamura and others 2011). A pairwise distance approach
was taken to avoid excluding a high percentage of aligned
columns associated with sporadic nucleotide ambiguities in indi-
vidual sequences. A 20 per cent uncorrected nucleotide distance
threshold between capsid sequences was used to deﬁne distinct
strains (Radford and others 2001b, Prikhodko and others 2014).
Results
Study sample
A total of 426 samples were collected from 13 sites in ﬁve coun-
tries. For 17 samples, the viral status could not be assessed due
to bacterial overgrowth. For the remaining 409, FCVand FeHV-1
was isolated from 91 (22.2 per cent) and 18 (4.4 per cent),
respectively (Table 2). For FCV, 16.2 per cent and 34.2 per cent of
healthy and sick (at least one clinical sign) cats tested positive
for FCV, respectively. For FeHV-1, the ﬁgures were 2.6 per cent
and 8.0 per cent.
Risk factors for FCV infection
Complete information about all the variables considered within
the multivariable model was only available for 299 samples. The
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ﬁnal model included the continuous variables age and a quad-
ratic term for age (age2), as well as the categorical variables vac-
cination status against FCV (FCV-V) and whether or not the
animal was presenting with LGSC, and the two-way interac-
tions FCV-V by age and FCV-V by age2 (Table 3). Other individ-
ual clinical signs were not found to be signiﬁcant in this
population.
Cats presenting with LGSC were 9.33 (95% CI 3.18 to 29.45)
times more likely to present with FCV infection than cats
without LGSC. The relationship between the probability of FCV
infection and age and vaccination status was more complex due
to an interaction between these risk factors. In short, in unvac-
cinated animals (n=119) there was a reduction in risk each
month for the ﬁrst 8 years, followed by a plateau for the next
2.5 years and an increase again every month for the next
10 years (Fig 2). In vaccinated animals (n=218), there was an
increase in risk each month for the ﬁrst 8.5 years, followed by a
plateau for the next 1.5 years and a decrease every month for the
next 12.5 years (Fig 2). In vaccinated animals up to 48 months of
age, the probability of being FCV infected was lower than in
unvaccinated animals of similar ages. From 48 months of age,
95% CIs of the probability for FCV infection in vaccinated and
unvaccinated animals overlapped, indicating a similar probability
between both groups of animals during that age (Fig 2). The
main effect of vaccination on the odds of FCV infection was not
signiﬁcant for animals with a centred age of 0 (i.e. a mean age of
71.7 months, Table 3 and Fig 2). One limitation of the study was
the small sample size, especially for older animals, reﬂected by
wide CIs in the predicted probability of FCV infection for those
animals (Fig 3).
Visual inspection of the data indicated a linear relationship
between the percentage of cats testing positive for FCV and
NCH (Fig 1b). The number of cats living in a household was
found to be signiﬁcantly associated with the probability of being
FCV infected on the univariable analysis. Thus, for one-unit
increase in NCH, the odds of being FCV infected increase 1.5%
(OR=1.015, 95% CI 1.004 to 1.034, p=0.043).
Sequence analysis
In total, 72 consensus sequences of the major immunodominant
region of the FCV capsid were obtained from the 91 FCV isolates
(Table 2). This included 71 clear consensus sequences containing
a small number (<5 per cent) of ambiguous nucleotide positions
typical for a calicivirus (Fig 3a). In contrast, one sample
(FR1_11), contained many ambiguities strongly suggesting a
mixed infection (Fig 3b). One of the two sequences in this
sample was present in a clear majority allowing FR1_11
sequence to be manually ‘split’ into its predicted major and
minor sequences, as well as its consensus (average). Whilst the
accuracy of these three individual sequences is likely to be lower,
the authors included them to gain further insight into the diver-
sity of viruses circulating in this population.
Two additional samples (FR1_37 and FR1_40) gave very clear
sequence, and were also identiﬁed as mixed infections. However,
unlike FR1_11, the two sequences were present in approximately
equal proportions making it impossible to manually resolve
them (Fig 3c). These sequences were not available for further
analyses and would require a cloning approach to separate them.
The ﬁnal capsid phylogeny (Fig 4a) included 74 usable
sequences (71 consensus, three for FR1_11). In total, 46 strains
(pairwise genetic distance >20 per cent) were identiﬁed; the
number of strains in each country and site ranged from 5 to 12
and 1 to 9, respectively (also Table 2). There was no evidence of
wide-scale clustering at the geographical level; rather strains
from each country were dispersed throughout the tree.
Of the 46 strains identiﬁed, 32 were represented by single
sequences, the remaining 14 each being represented by more
than 1 isolate and supported by bootstrap values of >75 per cent
(A–N on Fig 4a). The most numerous of these was strain A (9
samples and 11 sequences, including 3 for FR1_11). Of these 14
strains, 13 were geographically restricted to single sites, the
exception being strain M, found in two sites in France (FR1_43
and FR4_02). Eight of these strains had low levels of diversity
(<5 per cent) suggestive of relatively acute or recent infection.
The remaining six strains (A, C, D, G, M and N) showed greater
diversity (5–20 per cent); these high levels of strain diversity
have been found previously in endemically infected households
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FIG 1: Percentage of cats testing positive for feline calicivirus (FCV) by age−years (a) and by number of cats living in the same household (b)
TABLE 1: Primers used for partial capsid and polymerase gene
amplification
Primer Sequence (50→30)
Binding site
(nt)*
Capsid primers
M13cap2F CAGGAAACAGCTATGACCCCTTTGTCTTCCARGCHAAYCG 6406–6428
T7cap2R TAATACGACTCTCAATAGGGCCTCACCAATTCCNGTRTANCC 6934–6913
A1
forward
CCCTTCGTCTTTCAGGCCAACCG 6406–6428
A2
reverse
CCTCGCCAATCCCAGTGTAGCC 6934–6913
P1
forward
CCGTTTGTGTTTCAAGCAAACCG 6406–6428
p2
reverse
CCTCACCTATACCAGTGTAACC 6934–6913
M13cap1F CAGGAAACAGCTATGACCCVTTTGTNTTYCARGCHAAYCG 6406–6428
T7cap1R TAATACGACTCTCAATAGGGSYTCDCCRATNCCNGTRTANCC 6934–6913
Polymerase primers
M13_53D CAGGAAACAGCTATGACGAYATGATGACYTAYGGKGAYGAYGG 4766–4791
T7_33D TAATACGACTCTCAATAGGGCCGCGCYTCCACRCCRTTRAAYTG 5251–5228
Underlined regions illustrate the M13 forward and T7 reverse primer binding site
sequences used for sequencing amplicons produced with these otherwise
degenerate primers. Nucleotide sequences are shown using the single-letter IUB
codes for degeneracy: R=A/G purine; Y=T/C pyrimidine; K=T/G
*Nucleotide numbers of the binding sites relate to feline calicivirus (FCV) strain F9
(GenBank accession no. M86379) (Carter and others 1992)
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(Coyne and others 2007b). Four of the strains (D, J, L and M)
were present in more than one household/colony (data not pre-
sented). Five of the households had more than one strain of virus
(range two to six; Fig 4a).
None of the sequences obtained clustered with live vaccine
strain FCV-F9 (as represented by a published sequence M86379)
or with the inactivated vaccine strain FCV_255 (data not pre-
sented). The median uncorrected nucleotide distances between
F9 and sequences obtained in this study were 39.2 per cent (SD
3.1). This was similar to that obtained when the sequences
obtained in this study were compared pairwise with themselves
(median 40.1 per cent, SD 6.9).
Phylogenetic analysis of partial polymerase sequences was
generally congruent with that based on the capsid (Fig 4b).
However, the two sequences in polymerase clade O (GR1_26
and 35) were identiﬁed as distinct strains based on their capsid
sequence suggesting possible recombination. No capsid sequence
was available for those isolates in polymerase clade P (GE2_22
and 24). A similar ﬁnding was apparent for capsid clade L con-
taining GR1_07 and 22; these sequences were closely related
based on their capsid sequences but dispersed as distinct strains
in the polymerase phylogeny. Finally, sequences clustering in
clades M and N of the capsid phylogeny, albeit on the margins
of the strain diversity threshold (20 per cent) of the present
study, were also absent from the polymerase phylogeny.
Discussion
Previously the authors have been reconstructing the molecular
epidemiology of FCV at a local and national level in the UK.
These studies have pointed to both high FCV prevalence and
strain diversity, produced by a combination of rapid evolution
and occasional geographical dispersal. Here the authors report
for the ﬁrst time how FCVs are dispersed internationally,
showing that, subject to limitations associated with the authors’
sampling methodology, FCV prevalence remains high across
Europe, with little evidence for wide geographical dispersal of
individual strains.
The isolation rates reported here are somewhat higher than
previously reported, possibly reﬂecting different sampling meth-
odologies. In two previous UK studies, in which cats were not
selected based on clinical signs, isolation rates of 10 per cent
(Porter and others 2008) and 9–11 per cent (Coyne and others
2012) for FCVand <1 per cent for FeHV-1 were achieved. In con-
trast, in the study reported here, some of the 426 cats were
recruited speciﬁcally based on disease, notably the presence of
LGSC (N=26; 6 per cent). This inclusion rate is much higher
than would be expected in the general population where the
prevalence of LGSC is estimated to be 0.7 per cent (Healey and
others 2007). Since previous studies have shown this condition
to be strongly associated with FCV (Belgard and others 2010),
with 80 per cent or more of cats testing positive (Knowles and
others 1989), over-representation of such cases in the study
population might be expected to increase the FCV prevalence
over that found when cats were more randomly recruited
(Radford and others 2007).
TABLE 2: Summary of samples, isolates, amplification and strains identified in each country and site
Country
France UK Portugal
Greece
Germany
TotalSite FR1 FR2 FR3 FR4 FR5 Total UK1 UK2 Total PT1 PT2 Total GR1 GE1 GE2 GE3 Total
Samples (N) 41 7 33 7 14 102 49 34 83 48 32 80 42 40 28 34 102 409
FCV Positive, N
(%)
17
(41)
1
(14)
1
(3)
2
(29)
6
(43)
27
(26)
9
(18)
4
(12)
13
(16)
14
(29)
4
(13)
18
(23)
10
(24)
10
(25)
8
(29)
5
(15)
23
(23)
91
(22)
FCV Capsid PCR+ 16 1 1 2 5 25 6 2 8 14 3 17 9 8 4 3 15 74
FCV Capsid
sequence
14 1 1 2 5 23 6 2 8 14 3 17 9 8 4 3 15 72
Strains 5 1 1 2 4 12 3 2 5 9 3 12 8 4 3 2 9 46
FCV, feline calicivirus
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FIG 2: Predicted probability of a cat being infected with feline
calicivirus by age and vaccination status. Black and grey lines depict
the predicted probability in a vaccinated and unvaccinated cat,
respectively. Shaded boundaries represent 95% CIs
TABLE 3: Final multivariable logistic regression model of
factors associated with FCV infection
Variable Beta OR
95% CI
P valueLower Upper
LGSC
No Reference
Yes 2.23 9.33 3.18 29.45 <0.001
Vaccinated
No Reference
Yes 0.35 1.42 0.54 4.07 0.5
Age centered* (months) −0.014 0.99 0.98 0.99 0.003
Age centred2 (months) 0.0002 1.0002 1.0001 1.0003 <0.001
Vaccinated×age centred
Not vaccinated, age
centred
Reference
Vaccinated, age
centred
0.03 1.03 1.016 1.05 <0.001
Vaccinated×age centred2
Not vaccinated, age
centred2
Reference
Vaccinated, age
centred2
−0.0004 0.9996 0.9993 0.9998 <0.001
*Age centred: mean age was 71.7 months
FCV, feline calicivirus; LGSC, lymphoplasmacytic gingivitis stomatitis complex
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Other risk factors associated with FCV shedding included
age and vaccination status, conﬁrming results of previous studies
(Porter and others 2008, Coyne and others 2012). In this popula-
tion, vaccinated cats up to 48 months of age were less likely to
shed FCV than unvaccinated animals of similar ages, suggesting
in this age group, vaccination may have reduced infection rates.
Experimental studies have shown both vaccinated cats (Pedersen
and Hawkins 1995, Poulet and others 2005) and cats recovered
from acute FCV infection (Povey and Ingersoll 1975) remain sus-
ceptible to subsequent infection. However, such previous expos-
ure is often associated with a reduction in the shedding of
subsequent heterologous challenge (Povey and Ingersoll 1975,
Poulet and others 2005), consistent with the reduced risk of
testing FCV positive identiﬁed here. The loss of a demonstrable
protective effect of vaccination on FCV infection over 48 weeks
of age could represent the acquisition of immunity in the unvac-
cinated cats following ﬁeld infection, a consequence of the high
prevalence of FCV in the population. However, since the authors
did not model here the time since last vaccine, the apparent loss
of protective effect may also reﬂect increasing time since the last
vaccination in older animals.
Sequence analyses identiﬁed 46 strains among the 72 isolates
sequenced, conﬁrming the high levels of strain diversity seen pre-
viously (Coyne and others 2012, Prikhodko and others 2014).
Although the authors have not assessed the antigenicity of these
viruses, it seems likely that because of the known localisation of
neutralising epitopes in the regions sequenced, such genetic
diversity would be associated with similar antigenic diversity.
These levels of diversity pose a continual challenge to FCV
control by acquired immune responses, something vaccine com-
panies evaluate in relation to the antigens they choose
(Hohdatsu and others 1999, Addie and others 2008, Porter and
others 2008). In this context, it was interesting that, despite the
time that has passed since its ﬁrst isolation (Bittle and others
1960), FCV-F9 has not become a phylogenetic outlier, remaining
within the genetic diversity of the more recent isolates
sequenced here. This suggests the evolution of the antigenic
domain of FCV may behave differently from other rapidly evolv-
ing viruses like inﬂuenza.
By comparing the phylogeny with the geographical origin of
the isolates, the authors found no evidence of widespread inter-
national spread of FCV strains. Among the 46 strains described,
32 were only represented by a single isolate, and in only 13 and
14 cases were multiple variants of strains found in the polymer-
ase and capsid phylogenies, respectively. These strain clusters
were always conﬁned to single countries, and generally to
individual sites within a country. There was some limited
support for geographical clustering beyond the existing strain
deﬁnition in the present study in several countries best exempli-
ﬁed by a Portuguese cluster of ﬁve isolates including those in
strain D (Fig 4a), suggesting occasionally more widespread and
longer-term virus transmission as suggested previously in Japan
(Sato and others 2002). However, the overall picture remains one
of lack of international promiscuity, very distinct from human
caliciviruses where some strains or variants such as human noro-
virus genotype ii.4 are widely distributed internationally
(Ramani and others 2014). The authors’ current hypothesis is
that the rate of FCV evolution is so high that evolutionary
signals become saturated rapidly, leading to a loss of phylogen-
etic resolution over relatively short time periods (Coyne and
others 2012). This will only be resolved when longer sequences
are obtained.
Some of the strains the authors identiﬁed were associated
with high levels of within-strain diversity, notably strains A, C,
D and G. These levels of diversity are reminiscent of those seen
in endemically infected, multicat households, where the authors
hypothesised that high levels of population immunity lead to
rapid evolution by positive selection (Coyne and others 2007b).
In ﬁve cases, individual households/communities of cats
were infected with more than one strain (Fig 4a). The most
extreme example was a Greek rescue shelter where all six isolates
sequenced were distinct strains. This observation suggests lots of
viruses coming together into a single population but with little
transmission, a pattern either attributable to very good internal
biosecurity (Radford and others 2001b, Coyne and others
2007a), or suggesting that the cats were sampled on arrival in
the shelter before transmission had a chance to occur. A more
detailed understanding of the population demographics and hus-
bandry of these populations may shed more light on the beha-
viours that underlie these phylogenetic patterns.
In the present study, the authors found no FCV F9-like
sequences, a common strain used in live vaccines. This is in con-
trast to previous studies which have reported albeit rare occur-
rences of F9-like viruses in the general cat population (Radford
and others 2001a, Coyne and others 2007b, 2012). The origins
of these F9-like viruses are unknown but because of their
reported close sequence similarity to the original F9 sequence, it
seems reasonable they would have originated from regular use of
live vaccines containing this strain. The authors’ failure to ﬁnd
them in this study may reﬂect the fact that cats within 1 month
of receiving a live vaccination were excluded from the study
population. Together, this suggests that on the rare occasions
FIG 3: Examples of types of consensus sequences obtained. (a) Clear consensus with rare ambiguity (<5 per cent) in 71 sequences. (b) Mixed
sequence (>20 per cent ambiguous) but with clear major and minor sequences which can be manually resolved for further analyses (FR1_11).
(c) Mixed sequences (>20 per cent ambiguous), with approximately equal peak heights making meaningful manual resolution impossible
(FR1_37 and FR1_40)
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FIG 4: Unrooted Kimura 2-parameter Neighbour joining tree of (a) 74 partial capsid sequences (including three sequences for FR1_11) and (b)
73 partial polymerase sequences obtained in this study. Each sequence has a unique ID made up of country code (FRance, GErmany GReece,
PorTugal and UK) and site number (1–5) followed by sample number. Those strains represented by more than a single sequence (<20 per
cent capsid divergence) are boxed, additionally labelled A–N, and the intrastrain capsid diversity indicated in the box. Where multiple
sequences come from a single household they are indicated by an additional symbol (□, ○, Δ, *, ☆). Two new strain clusters O and P with
high bootstrap support are also indicated. Where clustering varies between capsid and polymerase phylogenies, the sequences are linked in
each phylogeny by a thin grey line. The feline calicivirus (FCV) vaccine strain F9 is also included (GenBank accession No. M86379). The
percentage of replicate trees in which the associated taxa clustered together in bootstrap tests (1000 replicates) is shown next to the
branches; only bootstrap values >75 per cent are shown. Distances are drawn to scale and relate to the distance bar
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cats do shed vaccine-derived virus following vaccination, the dur-
ation is short, and the potential for onward transmission
limited, consistent with reversion to virulence assays and dis-
semination experiments conducted for registration of live vac-
cines. This allows these vaccine-derived viruses to sporadically
appear at a low level in the population in a state of evolutionary
stasis.
The close co-circulation of distinct strains, and lack of steri-
lising immunity in individual cats, provides an ideal opportunity
for mixed infections (Coyne and others 2006b). Sequence data
suggested such mixed infections both at the quasispecies
(within-strain) level and cats infected with more than one strain
(FR1_11, 37 and 40). These diverse populations within an indi-
vidual host provide an ideal opportunity for recombination (Lai
1992), and the identiﬁcation of several incongruences between
capsid and polymerase phylogenies presented here provide some
evidence of recombination in these populations. Recombination
is a feature of the evolution of many RNAviruses (Lai 1992), and
has been described previously for caliciviruses in general and
FCV in particular (Coyne and others 2006b); there is some evi-
dence that a hot spot for the necessary template switch exists at
the junction between ORF1 and ORF2, in between the polymer-
ase and capsid sequences generated in this study (Oliver and
others 2004, Bull and others 2005), driven by predicted RNA sec-
ondary structure (Jiang and others 1993, Porter 2004, Coyne and
others 2006b, Prikhodko and others 2014). Formal conformation
of recombination requires sequencing across the putative recom-
bination site, but was beyond the scope of this project.
For 19 (21 per cent) of the 91 samples that showed FCV-like
cytopathic effect in cell culture the authors were unable to gen-
erate PCR products, despite using several primer combinations
(see methods and table 1). This is a well recognised phenomenon
for RNA viruses, especially when trying to amplify the most
variable regions of the virus. In a previous study this ‘failure rate’
was much higher (30–45 per cent) (Coyne and others 2012), pos-
sibly reﬂecting an improvement in primer design and PCR tech-
nology in the present study. These samples refractory to
sequencing represent an intriguing resource for future studies
using new technologies such as next-generation sequencing
(Radford and others 2012).
Study limitations: This study is the largest of its kind to pro-
spectively study FCV evolution and epidemiology in Europe.
However, in order to make sample collection feasible, a
convenience-based study design was required. This may impact
some of the epidemiological and phylogenetic conclusions, limit-
ing their generalisability. Further analyses with a bigger sample
size would increase the power of the study. Ultimately, longer
sequences would be needed to conﬁrm recombination and to
increase the resolution of the phylogenies in space and time.
The authors have described for the ﬁrst time the molecular
epidemiology of a prospective sample of FCV isolates from a
sample of European countries, conﬁrming both the strain diver-
sity of FCV, and the lack of dominant strains within the
population.
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